| Literature DB >> 29423614 |
Matthias Baumann1, Astrid Grams2, Tanja Djurdjevic2, Eva-Maria Wendel3, Christian Lechner4, Bettina Behring5, Astrid Blaschek6, Katharina Diepold7, Astrid Eisenkölbl8, Joel Fluss9, Michael Karenfort10, Johannes Koch11, Bahadir Konuşkan12, Steffen Leiz13, Andreas Merkenschlager14, Daniela Pohl15, Mareike Schimmel16, Charlotte Thiels17, Barbara Kornek18, Kathrin Schanda19, Markus Reindl19, Kevin Rostásy20.
Abstract
Antibodies against the myelin oligodendrocyte glycoprotein (MOG-Ab) can be detected in various pediatric acquired demyelinating syndromes (ADS). Here, we analyze the spectrum of neuroradiologic findings in children with MOG-Ab and a first demyelinating event. The cerebral and spinal MRI of 69 children with different ADS was assessed in regard to the distribution and characteristics of lesions. Children with acute disseminated encephalomyelitis (n = 36) or neuromyelitis optica spectrum disorder (n = 5) presented an imaging pattern characterized predominantly by poorly demarcated lesions with a wide supra- and infratentorial distribution. Younger children also tended to have poorly defined and widespread lesions. The majority of patients with an isolated optic neuritis (n = 16) only presented small non-specific brain lesions or none at all. A longitudinally extensive transverse myelitis mainly affecting the cervical, and less often so the thoracic, lumbar, and conus regions, was detected in 31 children. The three children of our cohort who were then finally diagnosed with multiple sclerosis had at onset already demarcated white matter lesions as well as transverse myelitis. In conclusion, children with MOG seropositive ADS present disparate, yet characteristic imaging patterns. These patterns have been seen to correlate to the disease entity as well as to age of symptom onset.Entities:
Keywords: Acute disseminated encephalomyelitis; Magnetic resonance imaging; Multiple sclerosis; Myelin oligodendrocyte glycoprotein; Neuromyelitis optica spectrum disorder; Pediatric acquired demyelinating syndromes
Mesh:
Substances:
Year: 2018 PMID: 29423614 DOI: 10.1007/s00415-018-8781-3
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849